The most widely used test for cholesterol particle size is the NMR LipoProfile, a blood test that uses nuclear magnetic resonance spectroscopy to measure how many lipoprotein particles you have and how large they are. It is not part of a standard lipid panel, which only tells you how much cholesterol is floating around in your blood, not the size or number of the particles carrying it. Several other laboratory methods can also assess particle size, and there are even rough estimates you can make from a basic lipid panel. The distinction matters because two people with identical LDL cholesterol numbers can have very different heart disease risk depending on whether their cholesterol is packed into a few large particles or many small ones.
Why Particle Size Matters
A standard cholesterol test measures the total amount of cholesterol riding inside your LDL particles. Think of it like measuring the total weight of cargo in a fleet of trucks without counting how many trucks there are or how big each one is. Two fleets can carry the same total weight, but one might use a handful of large trucks while the other uses dozens of small vans. The biological difference is real: smaller, denser LDL particles appear to be more dangerous. They slip more easily through the walls of arteries, linger in the bloodstream longer because LDL receptors on cells don’t grab them as efficiently, and are more prone to oxidation, a chemical change that triggers inflammation and plaque buildup.
A subfraction of LDL known as small dense LDL, with particles roughly 15 to 20 nanometers across, has been found to play a disproportionately large role in driving atherosclerosis, even in people whose overall cholesterol numbers look normal.1PubMed Central. Small dense LDL: An underestimated driver of atherosclerosis These particles promote the formation of foam cells (the fat-laden immune cells that make up arterial plaque), worsen endothelial dysfunction, and destabilize existing plaques.2PubMed Central. LDL atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review
Because each LDL particle carries a variable amount of cholesterol, and smaller particles carry less per particle, someone with lots of small dense LDL can have a “normal” LDL cholesterol reading while actually carrying a dangerously high number of particles.3PubMed Central. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number That discordance between cholesterol concentration and particle count is the central reason particle-size testing exists.
The Main Testing Methods
Several laboratory techniques can break down your LDL into subfractions. They approach the problem from different angles and don’t always produce identical results, which is one of the ongoing frustrations in this field. Here are the methods you’re most likely to encounter.
NMR LipoProfile
Nuclear magnetic resonance spectroscopy is the most commercially available particle-size test in the United States, marketed primarily by a company called Labcorp (formerly LipoScience). A standard blood draw is sent to a specialized lab, where the sample is exposed to a magnetic field. Different-sized lipoprotein particles emit distinct signals, allowing the instrument to count and size them simultaneously. The test reports particle numbers for LDL, HDL, and VLDL, along with average particle sizes and a risk category.4PubMed Central. Clinical Relevance of Nuclear Magnetic Resonance LipoProfile One of its key outputs is LDL particle number (LDL-P), which many researchers consider a stronger predictor of cardiovascular risk than LDL cholesterol alone.
Gradient Gel Electrophoresis
This older technique separates LDL particles by running them through a gel with progressively smaller pores. Smaller particles migrate farther, and the resulting pattern reveals the size distribution. It is the method that originally defined the concept of “pattern A” (mostly large, buoyant LDL) versus “pattern B” (mostly small, dense LDL). Gradient gel electrophoresis (GGE) is considered a reference method in research settings but is less commonly ordered in routine clinical practice because it’s labor-intensive.5PubMed Central. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease
Vertical Auto Profile (VAP)
The VAP test uses ultracentrifugation with a vertical rotor to separate lipoproteins by density in a single spin. It produces a detailed cholesterol profile across all the major lipoprotein classes and their subfractions, including four LDL subclasses (LDL-1 through LDL-4) and a measure of LDL peak time that is directly proportional to LDL size.6PubMed. Cholesterol profile measurement by vertical auto profile method The VAP was popular through the 2000s and early 2010s, but the original provider (Atherotech) went out of business in 2016. Some labs still offer ultracentrifugation-based subfraction testing, though the specific VAP brand is largely historical at this point.
Ion Mobility
Ion mobility analysis converts lipoprotein particles into an aerosol and measures their size as they drift through an electric field. It directly counts and sizes individual particles, making it conceptually similar to NMR but using a different physical principle. Ion mobility is used by Quest Diagnostics as the basis of its “Cardio IQ” advanced lipid panel. It was one of the four methods compared head-to-head in a study examining which best predicted progression of coronary artery disease.5PubMed Central. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease
Pattern A vs. Pattern B
When your results come back, the most common shorthand for particle size is the pattern classification. Pattern A means your LDL is predominantly large and buoyant. Pattern B means you have a predominance of small, dense particles. Pattern B isn’t just about particle size in isolation; it tends to travel with a cluster of other metabolic features. People with pattern B typically have higher triglycerides, lower HDL cholesterol, and higher insulin resistance compared to those with pattern A.7PubMed. LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women In fact, men with pattern B in one study had comparable LDL cholesterol to pattern A men but significantly higher insulin levels and insulin resistance.8PubMed Central. Reversal of Small, Dense LDL Subclass Phenotype by Normalization of Adiposity
Pattern B is essentially a flag for broader metabolic trouble. If your doctor tells you that you have predominantly small dense LDL, it’s worth looking at the whole picture: your triglycerides, your fasting glucose, your waist circumference. Addressing those upstream factors is usually the most effective way to shift particle size.
Can You Estimate Particle Size Without the Fancy Test?
Yes, roughly. The ratio of your triglycerides to your HDL cholesterol, both of which appear on a standard lipid panel, is a surprisingly decent proxy for LDL particle size. In patients with type 2 diabetes, this ratio correlated more strongly with LDL size than triglycerides or HDL cholesterol alone.9PubMed. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels In overweight youth, a triglyceride-to-HDL ratio above 3 was associated with substantially higher concentrations of small dense LDL and smaller average particle size.10PubMed Central. Surrogate Lipid Markers for Small Dense Low-Density Lipoprotein Particles in Overweight Youth
Among Asian Indians, a slightly higher cutoff ratio predicted the small dense phenotype with good accuracy.11The American Journal of Cardiology. Accuracy of the Ratio of Triglycerides to High-Density Lipoprotein Cholesterol for Predicting Low-Density Lipoprotein Cholesterol Particle Sizes, Phenotype B, and Particle Concentrations Among Asian Indians The exact cutoff varies by population and ethnicity, so it’s not a precise substitute for direct measurement. But as a quick and free sanity check, if your triglycerides are low and your HDL is high, you’re very likely carrying mostly large LDL. If your triglycerides are elevated and your HDL is low, you probably have a lot of small dense particles, even if your LDL cholesterol looks fine.
One thing the triglyceride-to-HDL ratio cannot tell you is your actual LDL particle number. And that number, not just the size, may be the more important piece of the puzzle.
Particle Number vs. Particle Size
Researchers have debated for years whether what really matters is the number of LDL particles or their size. The two are correlated: people with lots of small particles tend to have a high particle count. But the correlation isn’t perfect, and when they diverge, particle number seems to win. Each LDL particle contains one molecule of apolipoprotein B (apoB), so measuring apoB gives you an indirect count of your total atherogenic particles. About 85 to 90 percent of apoB particles are LDL.12PubMed Central. Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease
A large study of women found that when LDL cholesterol was low but particle-based measures like apoB or LDL-P were high, coronary risk was substantially underestimated. The hazard ratio for coronary events roughly doubled or tripled in women whose particle numbers were elevated despite having below-median LDL cholesterol. Conversely, women with high LDL cholesterol but low particle counts had much lower risk than their cholesterol numbers suggested.13PubMed Central. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events After adjusting for other risk factors, coronary risk was still misestimated by about 20 to 50 percent in women with discordant cholesterol and particle levels.
This is the practical argument for advanced lipid testing in a nutshell: your LDL cholesterol might be lying to you, in either direction. Particle-based measures can catch that mismatch.
Who Should Actually Get Tested
Most major cardiology guidelines do not recommend advanced lipid testing for routine screening. A standard lipid panel is still the foundation. But particle testing has a reasonable role in people whose risk is ambiguous, and several expert groups have suggested it for specific situations: people with a family history of early heart disease, postmenopausal women, and those who land in the “intermediate risk” category on standard calculators, especially if they’re close to the threshold for high risk.14PubMed. The role of advanced lipid testing in clinical practice
People with metabolic syndrome, insulin resistance, or type 2 diabetes are another group where the standard numbers can be misleading. Their LDL cholesterol may be unremarkable while their particle count and small dense LDL concentration are elevated. Patients with diabetic nephropathy, for instance, have a dramatically higher prevalence of small dense LDL compared to both healthy controls and diabetics without kidney complications.15Atherosclerosis. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia
A cost-effectiveness analysis estimated that testing 10,000 intermediate-risk patients with LDL-P and then treating those in the highest decile with moderate-intensity statin therapy would prevent 17 cardiovascular events and save over $300,000 over five years, while adding about 13 quality-adjusted life years.16Circulation: Cardiovascular Quality and Outcomes. Abstract 232: Cost-effectiveness Analysis of Lipoprotein Subfraction Testing in Patients at Intermediate Risk of Cardiovascular Events That’s a modest benefit at the population level, but for the individual who avoids a heart attack because the test revealed hidden risk, it’s substantial.
Shifting Your Particle Size
If your results come back unfavorable, the interventions that help are largely the same ones your doctor would recommend for metabolic health in general, with a few nuances worth knowing.
Reducing carbohydrate intake has the most consistent effect on LDL particle size. A systematic review and meta-analysis of trials found that carbohydrate-restricted diets increased LDL peak particle size and reduced total LDL particle number, with a shift away from small dense particles toward larger ones. Part of this effect appeared to be driven by the weight loss that tends to accompany carbohydrate restriction.17The American Journal of Clinical Nutrition. Effect of carbohydrate-restricted dietary interventions on LDL particle size and number in adults in the context of weight loss or weight maintenance: a systematic review and meta-analysis A small trial in statin users found that adding a low-carbohydrate diet increased LDL particle size within six weeks, even though their overall LDL cholesterol didn’t change.18The FASEB Journal. A very low carbohydrate diet and increased physical activity improve LDL particle size in individuals taking statins
Weight loss itself is a potent lever. Research has linked obesity with smaller LDL and HDL particles, and moderate weight loss through calorie restriction with an increase in LDL particle size.8PubMed Central. Reversal of Small, Dense LDL Subclass Phenotype by Normalization of Adiposity Exercise appears to have a complementary effect, more strongly shifting HDL particle size upward than LDL, but contributing to the overall metabolic improvement that drives the change.
What Statins Do and Don’t Do to Particle Size
This is where people get surprised. Statins are the most effective drugs for lowering LDL cholesterol and reducing cardiovascular events, but their effect on particle size is more complicated. One study found that while statins reduced total LDL cholesterol and the absolute amount of small dense LDL, the proportion of small dense LDL among remaining particles actually went up.19PubMed Central. Statins do not decrease small, dense low-density lipoprotein In other words, statins shrink the whole fleet of particles, but the remaining fleet is relatively more concentrated in the small dense variety.
That said, high-dose statin therapy may perform differently. A trial comparing high-dose rosuvastatin to low-dose therapy found that the higher dose significantly reduced absolute levels of small dense LDL and oxidized LDL.20PubMed. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL The message isn’t that statins are bad for particle size; it’s that standard-dose statins alone may not fully address a small-dense-LDL problem, and lifestyle changes (especially carbohydrate reduction and weight loss) remain important even if you’re already on medication.
Limitations of Current Testing
Before you rush to order a particle-size test, some honest caveats. The different testing methods don’t measure exactly the same thing, and they don’t always agree with each other. NMR measures particle number and size by magnetic signal. GGE separates by physical size. VAP separates by density. Ion mobility separates by aerodynamic diameter. A study that compared all four methods head-to-head for their ability to predict coronary artery disease progression found meaningful differences in which subfractions each method identified as most predictive.5PubMed Central. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease There’s no universally agreed-upon “gold standard” for clinical use.
NMR-derived LDL particle number and apoB are strongly correlated but not interchangeable. In a large clinical cohort, the correlation between the two was strong, but substantial discordance still existed at the individual level, and that discordance was linked to insulin resistance.21Journal of Clinical Lipidology. Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice Meanwhile, a simpler measure like the total apoB-to-LDL-cholesterol ratio does not reliably predict particle size on its own.22PubMed. The total apolipoprotein B/LDL-cholesterol ratio dose not predict LDL particle size
Insurance coverage varies widely. Many insurers will cover NMR or ion mobility testing if the ordering physician documents a clinical reason, such as a strong family history, metabolic syndrome, or intermediate risk with uncertain treatment decisions. Without documentation, you may pay out of pocket, typically somewhere in the range of $40 to $100 at direct-to-consumer labs.
Children and Particle Size
Advanced lipid testing is uncommon in children, but the research that does exist shows the same metabolic patterns appearing early. In a study of healthy seven-year-olds, children whose average LDL particle size fell below the median already showed higher insulin levels and lower HDL cholesterol, the same cluster of metabolic warning signs seen in adults with pattern B. The findings suggest that unfavorable particle profiles can take root well before adulthood, particularly in children who are overweight or have a family history of metabolic disease. For now, pediatric use of particle-size testing remains largely a research tool rather than a routine clinical recommendation.